Cargando…

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer

In advanced non-small cell lung cancer (NSCLC), response to immunotherapy is difficult to predict from pre-treatment information. Given the toxicity of immunotherapy and its financial burden on the healthcare system, we set out to identify patients for whom treatment is effective. To this end, we us...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donker, H. C., van Es, B., Tamminga, M., Lunter, G. A., van Kempen, L. C. L. T., Schuuring, E., Hiltermann, T. J. N., Groen, H. J. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121673/ https://www.ncbi.nlm.nih.gov/pubmed/37085581 http://dx.doi.org/10.1038/s41598-023-32499-3

Ejemplares similares

Immune microenvironment composition in non‐small cell lung cancer and its association with survival
por: Tamminga, Menno, et al.
Publicado: (2020)

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
por: Tamminga, Menno, et al.
Publicado: (2019)

Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients
por: Tamminga, Menno, et al.
Publicado: (2020)

Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch(®) and ISET
por: Tamminga, Menno, et al.
Publicado: (2020)

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
por: van der Leest, Paul, et al.
Publicado: (2021)

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
por: Wei, Jiacong, et al.
Publicado: (2018)

Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients
por: van der Leest, Paul, et al.
Publicado: (2023)

Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients
por: van der Leest, Paul, et al.
Publicado: (2020)

Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer
por: Saber, Ali, et al.
Publicado: (2016)

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
por: Koopman, Bart, et al.
Publicado: (2022)

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression
por: van der Wekken, A. J., et al.
Publicado: (2017)

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
por: Koopman, Bart, et al.
Publicado: (2021)

Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome
por: Kerner, Gerald S. M. A., et al.
Publicado: (2013)

Classification of Cells in CTC-Enriched Samples by Advanced Image Analysis
por: de Wit, Sanne, et al.
Publicado: (2018)

An exploratory study of volumetric analysis for assessing tumor response with (18)F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC)
por: Kerner, Gerald S. M. A., et al.
Publicado: (2016)

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing
por: Saber, Ali, et al.
Publicado: (2016)

Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review
por: Yu, Da-Ping, et al.
Publicado: (2017)

An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients
por: Wei, Jiacong, et al.
Publicado: (2020)

Trends in Medicare Payments for Beneficiaries With Aortic Stenosis
por: van Bakel, Pieter A. J., et al.
Publicado: (2022)

Qualitative exploration of factors influencing the plan selection process by Medicare beneficiaries
por: Zhao, Yi, et al.
Publicado: (2021)

Rasch analysis of the Patient and Observer Scar Assessment Scale (POSAS) in burn scars
por: van der Wal, Martijn B. A., et al.
Publicado: (2011)

Beneficiary Perspective
por: Davis, Karen
Publicado: (1996)

Beneficiaries of Rehabilitation
por: Bickenbach, Jerome, et al.
Publicado: (2021)

Non‐small‐cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy
por: Koopman, Bart, et al.
Publicado: (2021)

Beneficiary selection, use, and charges in two Medicare capitation demonstrations
por: Kasper, Judith D., et al.
Publicado: (1988)

Medicare Part D: Selected Issues for Pharmacists and Beneficiaries in 2007
por: Kilian, Janet, et al.
Publicado: (2007)

LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors
por: Oosting, S., et al.
Publicado: (2021)

Telemedicine use by medicare beneficiaries undergoing hepatopancreatic surgery during COVID-19
por: Shaikh, C.F., et al.
Publicado: (2023)

FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
por: Koole, Koos, et al.
Publicado: (2016)

Hand hygiene: a COVID beneficiary?
por: Prescott, K., et al.
Publicado: (2021)

Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2021)

Association of Medicaid Eligibility With Surgical Readmission Among Medicare Beneficiaries
por: Cher, Benjamin A. Y., et al.
Publicado: (2020)

Prevalence of scars: an international epidemiological survey in adults
por: Amici, J.M., et al.
Publicado: (2022)

Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer During the COVID-19 Pandemic
por: Hijmering-Kappelle, L.B.M., et al.
Publicado: (2022)

Benchmarking small-variant genotyping in polyploids
por: Cooke, Daniel P., et al.
Publicado: (2022)

Initiation of antihypertensive monotherapy and incident fractures among Medicare beneficiaries
por: Hargrove, Jennifer L., et al.
Publicado: (2017)

Participation in the Qualified Medicare Beneficiary Program
por: Neumann, Peter J., et al.
Publicado: (1995)

Beneficiary and Local Stakeholder Participation in Community-Based Nutrition Interventions
por: Robert, Rebecca C, et al.
Publicado: (2022)

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity
por: van den Broek, Daan, et al.
Publicado: (2020)

Medicare Beneficiary Satisfaction with Durable Medical Equipment Suppliers
por: Hoerger, Thomas J., et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_3nbca3p79uetbhrksss9hnkc4j